Nutex Health (NUTX) stock price is $198.99, up 4.05% on the day, as of Oct 20, 2026. It has a market cap of $1.37Bn and a P/E ratio of 7.64, and is classified in the Hospitals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap1.37 Bn
P/E7.64
P/S1.62
Div. Yield0.06
Total Debt (Qtr)39.70 Mn
Revenue Growth (1y) (Qtr)-13.62
Add ratio to table…
About
Nutex Health Inc. is a physician led healthcare services and operations company. It focuses on delivering care through a network of micro hospitals specialty hospitals and hospital outpatient departments. The company operates in twelve states across the United States and maintains a presence in both urban and suburban markets. In addition to its hospital operations Nutex Health Inc. manages a population health division that oversees independent physician association…
Nutex Health Inc. is a physician led healthcare services and operations company. It focuses on delivering care through a network of micro hospitals specialty hospitals and hospital outpatient departments. The company operates in twelve states across the United States and maintains a presence in both urban and suburban markets. In addition to its hospital operations Nutex Health Inc. manages a population health division that oversees independent physician association networks. The firm’s headquarters is located in Houston Texas and it was incorporated in Delaware in April 2000. The business model emphasizes collaboration with physicians who often hold equity in the facilities they serve. This structure aims to align clinical and financial interests across the organization.
Revenue is generated primarily from the hospital division which receives payments for services rendered at its facilities. These services include emergency room care inpatient stays behavioral health treatment and ancillary offerings such as imaging laboratory and pharmacy. Payments come from federal agencies private insurance carriers and patients through copays deductibles or self pay. The hospital division also benefits from professional services billed by affiliated physician entities that are consolidated as variable interest entities. The population health division contributes revenue through capitated fees paid per enrolled member and through management fees calculated as a percentage of those capitation amounts. The real estate division adds income by leasing owned properties to the hospital operating entities and by collecting mortgage interest on financed assets. Overall the company’s revenue streams are diversified across facility operations physician services and property ownership.
Nutex Health Inc. reports its operations through three segments the hospital division the population health management division and the real estate division.
The hospital division develops and operates micro hospitals specialty hospitals and hospital outpatient departments providing twenty four seven care. It offers a full spectrum of services including emergency room treatment inpatient care behavioral health support and ancillary services such as imaging laboratory and pharmacy. As of December 31 2025 the division owned and operated twenty six facilities spread across twelve states with nine additional micro hospitals in various stages of development. The division’s facilities typically range from fifteen thousand to twenty five thousand square feet and include seven to eight treatment rooms and two to ten inpatient beds. Revenue is derived from facility fees paid by federal agencies private insurers and patients. The division generally operates as an out of network provider which means it does not have negotiated rates with most insurance companies. Patients with commercial coverage often use out of network benefits and copays to settle their bills. The company expects to increase direct contracts with commercial payors over time to align reimbursement more closely with the value of its services.
The population health management division establishes and manages independent physician association networks. Through its management services organization it provides administrative billing collections human resources and other support services to affiliated physicians and groups. The division earns revenue from capitated payments that are based on the number of enrolled members receiving care. It also receives management fees that are calculated as a percentage of the gross capitation generated by the networks it oversees. As of the filing date the division oversaw four independent physician associations located in Los Angeles Houston South Florida and Phoenix. These networks collectively serve approximately thirty eight thousand members including those enrolled in Medicare Advantage commercial and Medicaid managed care plans. The division works to contract with health insurers to secure value based agreements that provide predictable revenue streams.
The real estate division owns the land and buildings that house the hospital facilities and leases them to the hospital operating entities. It also holds full ownership of the company’s headquarters building purchased in December 2025 and a fifty one percent interest in an Indiana based micro hospital facility. The division’s properties are frequently financed through mortgage loans with third party lenders which are secured by the real estate assets. Revenue is derived from lease payments received from the hospital operating entities and from ownership interests in the financed properties. The division may also provide accounting and administrative support to the real estate entities that are consolidated as variable interest entities. Since mid 2022 the company has deconsolidated several real estate entities after lenders released its guarantees on associated mortgage loans leaving two such entities currently reported as variable interest entities.
Nutex Health Inc. operates in a highly fragmented healthcare market where it competes with free standing emergency departments and large hospital systems that are also adopting micro hospital models. Its competitive advantages stem from its physician led structure which aligns incentives with medical staff and from its ability to deliver care in lower cost settings with shorter wait times. The company emphasizes a high quality patient experience and maintains strong relationships with physician partners who often hold equity in its facilities. While it faces competition from both national and local players its focus on community based micro hospitals and integrated physician networks differentiates it in the industry. The firm believes that its combination of clinical operations risk bearing population health and real estate ownership creates a unique platform that is difficult for competitors to replicate. Additionally the company’s scalable back office functions allow it to expand into new markets without duplicating administrative infrastructure.
The company serves patients seeking emergency inpatient and outpatient care across its hospital facilities. It also provides services to members of its independent physician association networks including those enrolled in Medicare Advantage commercial and Medicaid managed care plans. Payors such as federal agencies private insurance carriers and managed care organizations are key sources of revenue. Although specific customer names are not disclosed the base consists of individual patients physician groups and health plans operating in the twelve states where the company has a presence. The firm’s patient population includes individuals who value convenient access to care and who appreciate the reduced wait times offered by its micro hospital model. Physician partners benefit from ownership opportunities and from the administrative support provided through the management services organization. Health plans contract with the independent physician associations to deliver coordinated care to their members under capitated arrangements.
Sectors:Healthcare·Real EstateSector rationaleThe company's primary revenue is generated from its hospital division, which operates micro hospitals and specialty hospitals providing emergency, inpatient, and behavioral health care. It also manages population health through independent physician association networks, both of which fall under Healthcare. A secondary sector of Real Estate is justified because the company maintains a dedicated real estate division that owns the land and buildings for its facilities and earns revenue through leasing these properties to its operating entities.Industries:HospitalsHospitalsPrimaryNutex Health owns and operates a network of micro hospitals and specialty hospitals that provide 24/7 inpatient care, emergency room treatment, and behavioral health support. Revenue is primarily generated from facility fees paid by federal agencies, private insurers, and patients for these inpatient and surgical services.Healthcare ServicesHealthcare ServicesSecondaryThe company operates hospital outpatient departments and manages independent physician association networks through a management services organization. These activities deliver healthcare services in outpatient settings and provide administrative support to physician groups.Healthcare REITsHealthcare REITsSecondaryThe company has a dedicated real estate division that owns the land and buildings housing its hospital facilities and leases them back to the hospital operating entities. This aligns with the definition of a healthcare property owner where the tenants deliver healthcare.Classified using BQ-MICSCIK: 0001479681
Bull & bear
Investment Thesis
▲ Bull case
Nutex Health's core growth engine remains the independent dispute resolution (IDR) process under the No Surprises Act, which continues to deliver outsized returns despite market skepticism. The company reported that 85% of arbitration awards in the second half of 2024 favored providers, with median winning offers exceeding 4x the in-network rate—a structural advantage that is not fully reflected in current valuations. This high win rate, combined with an improving collection rate now exceeding 75% of legal determinations, creates a scalable revenue stream where each successfully arbitrated claim generates significant cash flow with minimal incremental cost. The recent federal IDR portal upgrade on July 1, 2025, streamlines submissions and reduces administrative friction, positioning Nutex to increase claim volume without proportional cost increases. Furthermore, the reintroduced No Surprises Act Enforcement Act, which imposes 3x penalties on insurers for late or nonpayment, directly addresses the collection lag and could accelerate cash conversion, turning arbitration wins into near-immediate revenue. This regulatory tailwind, coupled with Nutex's in-house expertise and HaloMD partnership, creates a durable moat in revenue cycle management that competitors cannot easily replicate.
The company's micro hospital model is demonstrating superior unit economics compared to traditional freestanding ERs, with mature hospitals showing 0.6% visit growth in Q2 but significantly higher observation and admission rates—indicating a shift toward higher-acuity, higher-reimbursement care. This clinical evolution, driven by intentional efforts to keep patients in-house for observation and inpatient care rather than transferring them out, directly boosts revenue per visit without requiring proportional increases in patient volume. As Jon Bates noted, reimbursement for inpatient services is substantially higher than ER, meaning that even modest visit growth translates to outsized revenue gains when case mix improves. With over 15 hospital projects in development and two confirmed openings by end-2025, Nutex is positioned to replicate this higher-acuity model across new markets, leveraging its proven ability to attract and retain complex cases. The Population Health Division, though currently flat in revenue, is expanding its IPA network to over 300 primary care physicians and 900 specialists, creating a referral feed that will further increase acuity and utilization at micro hospitals. This integrated care approach is not being adequately priced into the stock, as investors focus narrowly on headline visit growth while missing the underlying shift toward more profitable service lines.
Nutex's balance sheet strength and cash generation capacity are underappreciated, particularly given the temporary nature of the ongoing accounting restatement. The CFO explicitly confirmed that the restatement impacts only noncash stock-based compensation reclassifications, leaving revenue, gross profit, operating cash flow, adjusted EBITDA, and patient visits unaffected. As of June 30, 2025, the company held $96.7 million in cash and generated $78.2 million in operating cash flow for the first six months—figures that reflect real, sustainable earnings power. The $25 million share repurchase program authorized on July 30, 2025, signals management's confidence in intrinsic value, especially when combined with a business model generating over 50% gross margins and 30% adjusted EBITDA margins on a run-rate basis. Crucially, the company has minimal true debt ($15 million current, $20.5 million long-term) and is not reliant on external financing for growth, allowing it to fund hospital openings and acquisitions internally. This financial flexibility, paired with a pipeline of high-growth market entries, enables Nutex to pursue accretive opportunities without dilution or leverage risks—factors that are overlooked amid short-term noise around the 10-Q delay.
Nutex Health's core growth engine remains the independent dispute resolution (IDR) process under the No Surprises Act, which continues to deliver outsized returns despite market skepticism. The company reported that 85% of arbitration awards in the second half of 2024 favored providers, with median winning offers exceeding 4x the in-network rate—a structural advantage that is not fully reflected in current valuations. This high win rate, combined with an improving collection rate now exceeding 75% of legal determinations, creates a scalable revenue stream where each successfully arbitrated claim generates significant cash flow with minimal incremental cost. The recent federal IDR portal upgrade on July 1, 2025, streamlines submissions and reduces administrative friction, positioning Nutex to increase claim volume without proportional cost increases. Furthermore, the reintroduced No Surprises Act Enforcement Act, which imposes 3x penalties on insurers for late or nonpayment, directly addresses the collection lag and could accelerate cash conversion, turning arbitration wins into near-immediate revenue. This regulatory tailwind, coupled with Nutex's in-house expertise and HaloMD partnership, creates a durable moat in revenue cycle management that competitors cannot easily replicate.
The company's micro hospital model is demonstrating superior unit economics compared to traditional freestanding ERs, with mature hospitals showing 0.6% visit growth in Q2 but significantly higher observation and admission rates—indicating a shift toward higher-acuity, higher-reimbursement care. This clinical evolution, driven by intentional efforts to keep patients in-house for observation and inpatient care rather than transferring them out, directly boosts revenue per visit without requiring proportional increases in patient volume. As Jon Bates noted, reimbursement for inpatient services is substantially higher than ER, meaning that even modest visit growth translates to outsized revenue gains when case mix improves. With over 15 hospital projects in development and two confirmed openings by end-2025, Nutex is positioned to replicate this higher-acuity model across new markets, leveraging its proven ability to attract and retain complex cases. The Population Health Division, though currently flat in revenue, is expanding its IPA network to over 300 primary care physicians and 900 specialists, creating a referral feed that will further increase acuity and utilization at micro hospitals. This integrated care approach is not being adequately priced into the stock, as investors focus narrowly on headline visit growth while missing the underlying shift toward more profitable service lines.
Nutex's balance sheet strength and cash generation capacity are underappreciated, particularly given the temporary nature of the ongoing accounting restatement. The CFO explicitly confirmed that the restatement impacts only noncash stock-based compensation reclassifications, leaving revenue, gross profit, operating cash flow, adjusted EBITDA, and patient visits unaffected. As of June 30, 2025, the company held $96.7 million in cash and generated $78.2 million in operating cash flow for the first six months—figures that reflect real, sustainable earnings power. The $25 million share repurchase program authorized on July 30, 2025, signals management's confidence in intrinsic value, especially when combined with a business model generating over 50% gross margins and 30% adjusted EBITDA margins on a run-rate basis. Crucially, the company has minimal true debt ($15 million current, $20.5 million long-term) and is not reliant on external financing for growth, allowing it to fund hospital openings and acquisitions internally. This financial flexibility, paired with a pipeline of high-growth market entries, enables Nutex to pursue accretive opportunities without dilution or leverage risks—factors that are overlooked amid short-term noise around the 10-Q delay.
Nutex Health's reliance on the IDR process under the No Surprises Act exposes it to significant regulatory and legal risks that management is understating, particularly given the ongoing litigation against its third-party partner HaloMD. While Nutex insists it is not named in any lawsuits and operates in jurisdictions unaffected by insurer-led actions, the core allegations in the short seller report—regarding potential abuse of the arbitration system through inflated or improperly submitted claims—remain unaddressed in substance. The company's claim that it "meticulously adheres" to eligibility rules is undermined by the inherent complexity of bifurcated state laws and the federal IDR process, which creates ambiguity in determining whether claims qualify for arbitration. This complexity increases the risk of retroactive clawbacks or denials, especially as CMS has recently allowed reopening of awards based on narrow clerical or jurisdictional errors—a process that could be exploited by insurers to challenge past wins. Furthermore, the company's dependence on HaloMD for navigating this complex process introduces counterparty risk; if HaloMD faces adverse rulings or reputational damage, Nutex may lose critical expertise in claim submission and validation, directly threatening its primary revenue driver. The lack of transparency around how Nutex validates claim eligibility internally, despite insisting on compliance, raises concerns about the sustainability of its 85% win rate.
The company's reported financial strength is distorted by aggressive revenue recognition practices tied to arbitration outcomes, creating a risk of future restatements or revenue reversals. Nutex recognizes revenue based on legal determinations from the IDR process, not actual cash collection, and currently accrues revenue at approximately 75% of awarded amounts—implying that 25% of recognized revenue is based on expectations of future payment that may not materialize. While management cites improving collection trends, the fact that nearly $109 million of the $175 million in Q2 hospital collections was tied to arbitration revenue (62%) highlights how dependent earnings are on this volatile stream. If insurers successfully challenge awards through the newly permitted CMS reopening process or if the No Surprises Act Enforcement Act fails to pass, collection rates could deteriorate sharply. Additionally, the arbitration cost structure—reported as 26% to 28% of arbitration revenue—may be understated, as it likely excludes indirect costs such as legal overhead, internal compliance efforts, and opportunity costs of diverting staff from clinical operations. Any increase in these hidden costs would compress margins significantly, especially given that arbitration-related revenue now constitutes over 64% of hospital revenue in the first half of 2025.
Nutex Health's reliance on the IDR process under the No Surprises Act exposes it to significant regulatory and legal risks that management is understating, particularly given the ongoing litigation against its third-party partner HaloMD. While Nutex insists it is not named in any lawsuits and operates in jurisdictions unaffected by insurer-led actions, the core allegations in the short seller report—regarding potential abuse of the arbitration system through inflated or improperly submitted claims—remain unaddressed in substance. The company's claim that it "meticulously adheres" to eligibility rules is undermined by the inherent complexity of bifurcated state laws and the federal IDR process, which creates ambiguity in determining whether claims qualify for arbitration. This complexity increases the risk of retroactive clawbacks or denials, especially as CMS has recently allowed reopening of awards based on narrow clerical or jurisdictional errors—a process that could be exploited by insurers to challenge past wins. Furthermore, the company's dependence on HaloMD for navigating this complex process introduces counterparty risk; if HaloMD faces adverse rulings or reputational damage, Nutex may lose critical expertise in claim submission and validation, directly threatening its primary revenue driver. The lack of transparency around how Nutex validates claim eligibility internally, despite insisting on compliance, raises concerns about the sustainability of its 85% win rate.
The company's reported financial strength is distorted by aggressive revenue recognition practices tied to arbitration outcomes, creating a risk of future restatements or revenue reversals. Nutex recognizes revenue based on legal determinations from the IDR process, not actual cash collection, and currently accrues revenue at approximately 75% of awarded amounts—implying that 25% of recognized revenue is based on expectations of future payment that may not materialize. While management cites improving collection trends, the fact that nearly $109 million of the $175 million in Q2 hospital collections was tied to arbitration revenue (62%) highlights how dependent earnings are on this volatile stream. If insurers successfully challenge awards through the newly permitted CMS reopening process or if the No Surprises Act Enforcement Act fails to pass, collection rates could deteriorate sharply. Additionally, the arbitration cost structure—reported as 26% to 28% of arbitration revenue—may be understated, as it likely excludes indirect costs such as legal overhead, internal compliance efforts, and opportunity costs of diverting staff from clinical operations. Any increase in these hidden costs would compress margins significantly, especially given that arbitration-related revenue now constitutes over 64% of hospital revenue in the first half of 2025.